Morning Brief — Monday, August 24, 2026

Market Overview

Futures are modestly lower pre-bell as investors await details on U.S. sanctions against Iran, with the dollar at 3-month lows on Treasury buyback plans adding a macro overlay. Long-duration Treasury yields remain elevated after ending last week higher for the second consecutive week, pressuring growth multiples. The backdrop is constructive for commodities, gold, and international names, while rate-sensitive tech faces a modest headwind heading into the NVDA earnings catalyst later this week.

Claude’s Call

UP — The dollar weakness narrative is a genuine tailwind for commodity names, gold miners, and EM-exposed plays, and with NVDA earnings on deck as a potential market catalyst, dip buyers are likely to step in. The market drifts higher today on thin conviction — not a rip, but not a rollover either.

Top Movers

NSSC (+32.55%) — $50.49 → $54.78 (+8.5% upside) Thesis: This is the real deal — NAPCO posted a 29.3% EPS beat ($0.50 actual vs. consensus) with revenue up 10% YoY to $55.81M, and the recurring revenue model is exactly what the market rewards with a premium. The stock broke to a 6-month high today, trading at the top of its entire 6-month range with SMA-50 sitting way down at $37.81 — there’s no technical overhead, but after a 32% gap it’s already very extended. Fib 1.272 extension at $54.78 is your first logical target, but chasing a 32% gap open is a high-risk entry. Levels: Exit at Fib 1.272 extension $54.78; deeper target $60.21 (Fib 1.618). Support at Fib 23.6% retracement $46.81 — that’s your first line in the sand if this fades.

FCFS (+9.41%) — $225.28 → $245.03 (+8.8% upside) Thesis: FirstCash is firing on all cylinders — Q2 revenue beat with sales up 29.4% YoY to $1.07B, non-GAAP EPS of $2.50 beat by 4.8%, and the macro backdrop of inflation pressure driving pawn demand is a durable secular tailwind, not a one-quarter blip. The Zacks callout today adds a momentum layer. Technically, FCFS is at the 20-day high of $225.97 with the 6-month high at $232.11 just above — breaking through that sets up a clean run to Fib 1.272 at $245. Levels: Exit at Fib 1.272 extension $245.03; all-time high zone $232.11 is intermediate resistance. Support at Fib 23.6% $220.89 then SMA-50 $213.74.

VIRT (+11.01%) — $67.93 → $75.89 (+11.7% upside) Thesis: Virtu Financial is a direct beneficiary of market volatility expansion — as VIX expands on geopolitical uncertainty (Iran sanctions, elevated yields), Virtu’s market-making revenue accelerates. No single earnings catalyst today, but this is structural sector rotation into financials that benefit from volatility, not sympathy noise. RSI of 16.6 is deeply oversold on the 6-month chart and the stock is pressing the 20-day high at $67.93 — this is a legitimate breakout off an oversold base. SMA-50 at $60.06 is well below, giving room to run. Levels: Exit at Fib 1.272 extension $75.89; next stop $86.01 (Fib 1.618) if volatility stays elevated. Support at Fib 23.6% $61.03 then SMA-50 $60.06.

HMY (+6.9%) — $23.54 → $26.49 (+12.5% upside) Thesis: Harmony Gold is riding gold’s bull run, dollar weakness (3-month low on DXY), and the classic “rising gold price = leveraged upside for miners” trade. RSI of 77.9 is overbought but gold miner RSIs can stay elevated in bull runs — the Zacks Buy upgrade from June is still in play, and the stock is at a 6-month high. The macro setup (dollar weak, rates volatile, geopolitical risk from Iran sanctions) makes gold the obvious defensive play today. Watch for gold to confirm. Levels: Exit at Fib 1.272 extension $26.49; Fib 1.618 at $30.14 is the bigger target. Support at Fib 23.6% $21.13 — a stop below there makes sense.

MP (+9.1%) — $60.05 → $82.05 (+36.6% upside) Thesis: MP Materials is the clearest “policy tailwind meets operational momentum” story in the market right now. The Trump administration’s $500M critical minerals push, 1H26 Materials segment revenues up 80% YoY on surging NdPr production, and the dollar weakness backdrop all align. The stock is at the 20-day high of $60.05 but still 17% below the 6-month high of $72.65. Fib 38.2% retracement at $59.45 is just below current price — this is a technically clean entry zone. The Fib 1.272 extension at $82.05 represents 36% upside with strong policy support. Levels: Exit at Fib 1.272 extension $82.05; reclaim of $72.65 (6-month high) is the nearer resistance. Stop below Fib 38.2% at $59.45 or SMA-50 $51.80.

AMR (+8.09%) — $210.01 → $246.68 (+17.5% upside) Thesis: Alpha Metallurgical had a rough Q2 operationally (revenue -$57M YoY, guidance trimmed on terminal disruptions), but a director buying $2.9M of shares at current prices is a powerful insider signal that the washout is close to done. The stock is up 26% this week — that’s a significant short-covering/insider-driven squeeze off deeply oversold levels (RSI 27.35). At $210, it’s at the 20-day high, with SMA-50 far below at $160.77. This is a recovery bounce play, not a fundamentals story — be honest about that. Levels: Exit at Fib 1.272 extension $246.68; 6-month high $223.26 is near-term resistance. Stop at Fib 23.6% $202.94 — break there and the trade is done.

RELY (+7.93%) — $26.67 → $29.84 (+11.9% upside) Thesis: Remitly is a growth story with real legs — raised 2026 guidance, an active buyback program, 92% YTD stock return, and a 26% upside consensus analyst target. Dollar weakness is a direct tailwind for cross-border remittance volumes. RSI of 13.55 on the 6-month chart suggests the stock has been washed out despite strong fundamentals. Today’s +7.93% move is touching the 6-month high at $26.67 — a clean breakout level. Levels: Exit at Fib 1.272 extension $29.84; Fib 1.618 at $33.88 is the stretch target. Support at Fib 23.6% $23.92 then SMA-50 $23.43.

ALVO (+9.03%) — $4.83 → $5.29 (+9.5% upside) Thesis: BofA just initiated with a Buy and $7 price target (45% upside from here) citing FDA inspection closure and the company entering its most meaningful biosimilar launch cycle ever. That’s a hard catalyst with a tier-1 bank name behind it. The stock is at a 6-month high ($4.80). However, at $4.83 against a $7 target, risk/reward is compelling. This is early-stage biotech with binary risk, but the FDA overhang removal is the key unlocking event. Levels: Exit at Fib 1.272 extension $5.29 short-term; longer hold targets $5.91 (Fib 1.618) or the BofA $7 target. Support at Fib 23.6% $4.38, SMA-50 $3.69.

NTES (+6.98%) — $128.17 → $134.20 (+4.7% upside) Thesis: NetEase reported Q2 with gaming revenue up 10% YoY and gross margins expanding to 76.1% — solid execution. Dollar weakness is a tailwind for Chinese ADRs broadly, and the DCF analysis suggests 23-38% undervaluation. But at $128 against a Fib 23.6% support of $128.16, the stock is sitting right on support after a pullback from the $134.20 6-month high. Near-term upside is limited (only 4.7% to prior high), making this a hold rather than a chase. Levels: Exit at 6-month high $134.20; Fib 1.272 extension $141.16 is the next level if it breaks out. Support at Fib 38.2% $124.43, SMA-50 $126.83.

EZPW (+12.03%) — $32.22 → $38.46 (+19.4% upside) Thesis: EZCORP reported record pawn loan balances at $382M, 48% adjusted EBITDA surge, and Latin America momentum — and the CFO just presented at Canaccord’s Growth Conference, adding visibility. Like FirstCash, this is an inflation beneficiary with tangible earnings improvement. RSI of 5.48 on the 6-month chart is extraordinarily oversold — today’s move is the beginning of a mean reversion. Sits just below Fib 23.6% at $33.10. Levels: Exit at Fib 1.272 extension $38.46; 6-month high $35.59 is key resistance. Support at SMA-50 $31.32; stop below $31.

Headlines to Watch

“Dollar at 3-Month Lows on Treasury Buyback Plans” — Dollar weakness is the single biggest macro factor today; it’s a green light for gold miners (HMY, Harmony), rare earth plays (MP), and international names (NTES, ALVO). Position accordingly.
“US Futures Fall Pre-Bell as Investors Await Iran Sanctions Details” — Geopolitical uncertainty around Iran is a volatility catalyst — Virtu (VIRT) benefits directly from elevated VIX. Watch oil prices; a spike would hit consumer discretionary and benefit energy names not in today’s top 20.
“NVDA Earnings This Week” — The single most important earnings print of the week. WSB is 80% bullish with 157 mentions. NVDA at $213 is below its SMA-50 of $207.75 (just above it) and sitting at Fib 50% support at $200.22 — the technical setup looks constructive into the print. A beat could lift the entire semiconductor and AI ecosystem.
“Alpha Metallurgical Director Courtis Buys $2.9 Million Shares” — Insider buying at this scale is one of the most reliable single signals in equity research. Courtis now holds over 1 million shares. AMR at $210 is up 26% this week but still 43% off its all-time zone — this is a credible recovery signal.
“BofA Starts Bullish Alvotech Coverage with $7 Price Target” — A tier-1 initiation with 45% upside on a post-FDA-inspection name entering its peak launch cycle. Biotech initiations from BofA carry distribution weight — expect institutional interest to build through the week.
“US Stock Indices End Week Lower on Elevated Long-Duration Treasury Yields” — The 30-year yield rising for a second straight week is the primary risk to growth/tech valuations. Monitor the 30-year bond market — if yields continue higher, the NVDA earnings beat (if it materializes) will be partially neutralized by multiple compression.
“MP Materials 1H26 Materials Segment Revenue Jumps 80%” — This is genuine operational delivery against a tailwind of U.S. critical minerals policy. The $500M government push isn’t directed at publicly traded companies directly, but MP Materials is the clearest pure-play listed beneficiary. Don’t mistake policy rhetoric for guaranteed revenue — but NdPr production numbers are real.

Claude’s Top Picks

MP (+9.1% today, +2.2% week) — $60.05 → $82.05 (+36.6% upside) Valuation: No comps provided but at a $3.8B market cap with 80% revenue growth in its core segment and explicit government policy tailwinds, MP trades at a discount to the long-term value of its supply chain monopoly position. Upside: Dollar weakness + $500M government critical minerals program + NdPr production ramp = multi-week catalyst stack; Fib 1.272 at $82.05 is the technical target, and reclaiming the 6-month high at $72.65 would be a confirming breakout. Risk: Rare earth prices are volatile and government contract timing is unpredictable — if NdPr spot prices roll over or a policy announcement gets delayed, this gives back gains quickly; stop below Fib 38.2% at $59.45.

FCFS (+9.41% today, +4.9% week) — $225.28 → $245.03 (+8.8% upside) Valuation: No forward P/E provided, but at 29% YoY revenue growth with expanding margins in a consumer-stress environment, FCFS deserves a premium to consumer finance peers; 61% return since Zacks recommendation suggests multiple expansion is ongoing, not complete. Upside: Inflation-driven pawn demand is a secular tailwind, not a one-quarter phenomenon; the technical setup (at 20-day high, SMA-50 $213.74 far below) gives the stock room to test the 6-month high at $232.11 and then Fib 1.272 at $245. Risk: A sharp deceleration in consumer credit stress (unlikely near-term) or a negative macro shock could reverse the pawn cycle; the stock has already returned 61% in 12 months, limiting multiple expansion room.

VIRT (+11.01% today, +13.2% week) — $67.93 → $75.89 (+11.7% upside) Valuation: Market-making firms trade on earnings volatility — VIRT is cheap on a normalized earnings basis when VIX is elevated, as transaction volumes and spreads expand simultaneously; no peer comps provided but the business model accelerates in exactly this macro environment. Upside: Iran sanctions uncertainty + elevated Treasury yields + NVDA earnings week = volatility regime that is directly monetized by Virtu’s trading engine; RSI of 16.6 on the 6-month chart means this was extremely washed out before today’s breakout. Risk: If geopolitical tensions de-escalate rapidly and VIX collapses back to cycle lows, Virtu’s revenue reverts hard; breaking below Fib 23.6% at $61.03 would signal the trade is broken.

ALVO (+9.03% today, +24.5% week) — $4.83 → $5.91 (+22.4% upside) Valuation: Pre-profitability biosimilar developer; BofA’s $7 target implies the market is pricing in meaningful launch risk discount — FDA inspection closure reduces the single biggest overhang, making current valuation look conservative. Upside: BofA initiation with a $7 target on a $4.83 stock entering its peak launch cycle is a hard catalyst; institutional buying from the initiation should provide a floor and upward pressure over the next 1-2 weeks. Risk: Biosimilar launch execution is notoriously difficult — pricing pressure from reference biologics and competitor biosimilars can compress margins fast; this is a small-cap biotech, so position sizing matters.

HMY (+6.9% today, +21.1% week) — $23.54 → $26.49 (+12.5% upside) Valuation: Gold miner valuation is tied to gold price and cost structure — with dollar at 3-month lows and gold in a bull run, Harmony’s leveraged exposure to spot gold makes it attractive relative to gold ETF holders; RSI of 77.9 is high but gold miners can sustain overbought conditions during gold bull runs. Upside: Dollar weakness is the cleanest macro setup for gold miners; Harmony is a leveraged pure-play on gold prices with the Zacks Buy upgrade still live; Fib 1.272 at $26.49 is a realistic 1-2 week target if the gold rally holds. Risk: Gold is the driver, not company execution — any reversal in the dollar (especially if Iran sanctions are lighter than feared) or a surprise yield spike could pull gold back hard and take HMY down 10-15% quickly; RSI overbought at 77.9 means little margin for error.

Avoid

TOP (+6.4%, +27% week) — RSI of 105.98 is mathematically impossible in standard RSI (max is 100), signaling data anomalies consistent with a manipulated or illiquid micro-cap; the stock has run 111% YTD with virtually no legitimate fundamental coverage and a 39x P/B on rising losses — this is a momentum trap with zero fundamental support.

GENVR (+25.3%) — Volume ratio of 0.02 means this is an extremely illiquid name moving on essentially no volume; RSI of 178.52 is another impossible reading flagging data integrity issues; the 25% single-day move with no company-specific news beyond a dividend announcement weeks ago screams low-float manipulation — do not chase.

NSSC (+32.55%) — The earnings were genuinely strong, but a 32% gap-open on a security systems manufacturer is excessive; the stock is now at its 6-month high with RSI at 50 (neutral, not a clear signal) and already above Fib 1.272 extension territory relative to the move magnitude. The better trade is to wait for a pullback to Fib 23.6% support at $46.81 for a cleaner risk/reward entry — chasing a 32% gap is how you get trapped when the euphoria fades.

WSB Sentiment Check

NVDA — WSB says: BULLISH (80% bullish, 157 mentions, 481 upvotes) Claude says: AGREE — The technical setup actually supports this: NVDA at $213.31 is above SMA-50 ($207.75) and sitting between Fib 38.2% support ($208.54) and the prior 20-day high ($225.30). The setup is constructive into earnings — a beat on AI data center revenue could push toward $225-$235. This isn’t delusional; it’s the market’s most important earnings print and WSB is right to be watching. Risk: the stock has already priced in optimism, so a “beat but guide cautious” scenario sends it back to $208 support fast.

SLS — WSB says: BULLISH (80% bullish, 77 mentions, 1,493 upvotes) Claude says: PARTIALLY AGREE — Solaris Resources (copper/gold miner) has genuine fundamental support: EIA approval in Ecuador for Warintza, Royal Gold funding secured, 95% analyst upside targets, and a dollar weakness macro tailwind. But 1,493 upvotes on 77 mentions is disproportionate engagement suggesting retail herding. Technically, SLSR at $8.90 is above its SMA-50 ($8.11) with room to Fib 1.272 at $12.23 — the chart is constructive, but don’t mistake WSB attention for a sustainable catalyst.

MSTR — WSB says: BULLISH (80% bullish, 58 mentions, 2,078 upvotes) Claude says: DISAGREE — 2,078 upvotes is the highest engagement number here and it’s on a stock that is 38% below its 6-month high ($195.94) and currently trading at $121.82, sitting just above Fib 61.8% support at $125.72 (technically it’s already breached it). MSTR is a leveraged Bitcoin proxy — if BTC rallies, MSTR works. But the technical picture is a downtrend, not a base, and the “Bitcoin treasury” strategy has stretched the balance sheet. This is hopium until Bitcoin makes a decisive new high.

MU — WSB says: BULLISH (80% bullish, 55 mentions, 146 upvotes) Claude says: PARTIALLY AGREE — Micron at $915.64 is well below its 6-month high of $1,213.37 and below its SMA-50 of $962.94, sitting between Fib 38.2% ($872.77) and Fib 23.6% ($1,002.95) support/resistance levels. The memory cycle recovery thesis is real — HBM demand for AI training is genuine. But the stock is in a technical downtrend from peak, and with the 6-month chart showing a meaningful drawdown, the near-term setup is “recovering, not broken” — not a moonshot. WSB’s enthusiasm is early but not wrong directionally.

SNDK — WSB says: BULLISH (80% bullish, 48 mentions, 129 upvotes) Claude says: DISAGREE — SNDK at $1,455 is well below its 6-month high of $2,335 and its SMA-50 of $1,645.65, currently sitting near Fib 50% support at $1,431.17. The stock has been cut nearly in half from the high — that’s not a dip, that’s a trend. Flash storage demand is cyclical, and the current price is below both its 20-day low range midpoint and its SMA-50. Until SNDK reclaims $1,645 (SMA-50), this is a falling knife with a retail bid. The WSB thesis needs a catalyst — without one, this is a cyclical down-trade, not a recovery play.

Earnings Scorecard

NSSC — BEAT by ~29% EPS | Stock: +32.55% | Reported: Monday Before Open Genuinely strong beat on both EPS and revenue (10% YoY growth, record revenue), and the recurring revenue model deserves a premium re-rating — but a 32% single-day reaction for a security systems company is overdone; wait for the $46-47 pullback zone before entering as a new buyer.

MRVL — REPORTED ($2.92 EPS) | Stock: -5.58% | Reported: Pre-bell The -5.6% reaction despite a solid EPS print suggests the market wanted more from the Google partnership narrative or guidance — “sell the news” on a high-expectation AI chip name; the bar had been raised too high, and until there’s clarity on Google deal specifics, this is a hold-not-add.

XPEV — MISS ($-0.35 EPS) | Stock: -4.22% | Reported: Pre-bell Revenue miss with ongoing losses, even as the robotics unit raised $900M separately — the market is discounting the EV unit and pricing robotics optionality separately, which is a fair read; the -4.2% reaction may actually be insufficient given the magnitude of the miss — avoid.

BILI — REPORTED ($0.50 EPS) | Stock: -2.87% Bilibili’s muted decline on a positive EPS print suggests investors are frustrated by the pace of monetization — Chinese internet names trade on sentiment as much as fundamentals right now; the -2.9% reaction looks broadly fair; no edge here without a clearer monetization catalyst.

IREN — REPORTED ($0.77 EPS) | Stock: -1.86% IREN leading in AI revenue efficiency is the right narrative, but the modest decline suggests the print was in-line rather than a true beat — the AI compute hosting space is pricing in high growth already; the small reaction is justified.

AFRM — REPORTED ($1.10 EPS) | Stock: +1.86% Modest positive reaction on Affirm — the BNPL space has re-rated higher as consumer credit stress drives volumes, but +1.86% is a muted response; suggests the beat was modest and guidance didn’t dramatically exceed consensus. Hold existing positions; don’t chase.

SNPS — REPORTED ($4.38 EPS) | Stock: -1.69% Synopsys declining despite a solid EPS print is a classic “sell the news” on a high-multiple EDA software name — elevated Treasury yields are compressing multiples on long-duration software companies regardless of execution quality. The reaction is slightly overdone fundamentally, but the macro headwind is real.

CRWD — REPORTED ($-0.04 EPS) | Stock: +1.63% A slightly positive reaction on CrowdStrike despite a GAAP loss signals the market is focused on the right metrics (ARR growth, platform consolidation) rather than GAAP EPS. Cybersecurity spend is non-discretionary — this is a hold and add on weakness.

WSM — REPORTED ($8.91 EPS) | Stock: +1.09% Williams-Sonoma’s modest positive reaction on a strong EPS print reflects the nuance that home furnishing demand remains soft even as the company executes well on margins — the +1.09% is a fair and unsurprising reaction.

OKTA — REPORTED ($1.38 EPS) | Stock: -1.29% Okta continues to face a credibility gap post-security incident — a strong EPS print isn’t enough to overcome trust concerns and elevated churn fears; the -1.29% reaction is fair but the stock at $146 vs. a $146.23 analyst target implies zero expected upside. Avoid.

BNS — REPORTED ($5.25 EPS) | Stock: -1.38% Bank of Nova Scotia’s modest decline despite a solid EPS print reflects broader concerns about Canadian banking exposure to a slowing domestic real estate market — the reaction is justified; no edge here.

ESTC — REPORTED ($3.43 EPS) | Stock: -1.05% Elastic declining on a positive print signals the market is seeing decelerating growth momentum rather than expansion — in a rising yield environment, growth software names need to show acceleration, not just beat low bars. Fair reaction.

This brief is for informational purposes only and does not constitute financial advice. All technical levels and targets are based on the data provided. Past performance is not indicative of future results.